A clinical trial for patients with metastatic pancreatic cancer uses the new drug SM-88 in combination with other agents, to attack the tumor metabolism.
Scientists are testing a new drug that is an antagonist of stress hormone receptors, in combination with nab-paclitaxel, for advanced pancreatic cancer.
Dr. Matthew Katz reviews the study that compared neoadjuvant treatment with FOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic cancer.
This trial tests the effectiveness of three different novel drugs, including immunotherapy, added to standard treatment for advanced pancreatic cancer.
Tammy Richardson has focused her pancreatic cancer treatment choices on maintaining her quality of life, so she can travel and see family as much as possible.
Dr. Jennifer Knox is leading the NeoPancONE trial for a biomarker that indicates which patients will respond better to certain chemotherapy before surgery.